Palo Alto Investors’s Mirum Pharmaceuticals MIRM Stock Holding History

Palo Alto Investors’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.8M	Buy	348,808 +23,633	+7%	+$2.37M	5.64%	4
2026 Q1	$30M	Buy	325,175 +168,754	+108%	+$15.9M	4.59%	7
2025 Q4	$12.4M	Buy	156,421 +91,721	+142%	+$6.58M	1.72%	17
2025 Q3	$4.74M	Hold	64,700	–	–	0.88%	24
2025 Q2	$3.29M	Hold	64,700	–	–	0.7%	23
2025 Q1	$2.91M	Hold	64,700	–	–	0.56%	23
2024 Q4	$2.68M	Hold	64,700	–	–	0.41%	27
2024 Q3	$2.52M	Hold	64,700	–	–	0.33%	28
2024 Q2	$2.21M	Hold	64,700	–	–	0.26%	29
2024 Q1	$1.63M	Hold	64,700	–	–	0.18%	32
2023 Q4	$1.91M	Hold	64,700	–	–	0.17%	27
2023 Q3	$2.04M	Hold	64,700	–	–	0.19%	23
2023 Q2	$1.67M	Hold	64,700	–	–	0.14%	25
2023 Q1	$1.55M	Hold	64,700	–	–	0.13%	26
2022 Q4	$1.26M	Hold	64,700	–	–	0.11%	24
2022 Q3	$1.36M	Hold	64,700	–	–	0.11%	26
2022 Q2	$1.26M	Hold	64,700	–	–	0.11%	26
2022 Q1	$1.43M	Hold	64,700	–	–	0.11%	27
2021 Q4	$1.03M	Buy	+64,700	New	+$1.01M	0.07%	31

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Palo Alto Investors's MIRM Position: Q2 2026 in Review

Palo Alto Investors increased its Mirum Pharmaceuticals (MIRM) stake by 7.3% in Q2 2026, buying an estimated $2.37M and bringing the position to 348,808 shares worth $40.8M. The position accounts for 5.64% of the portfolio, ranked #4.

Palo Alto Investors first reported a position in MIRM in Q4 2021 and has held it in 19 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

Palo Alto Investors held 348,808 shares of Mirum Pharmaceuticals worth $40.8M as of Q2 2026.
Palo Alto Investors bought 23,633 Mirum Pharmaceuticals shares in Q2 2026, an estimated $2.37M.
Mirum Pharmaceuticals made up 5.64% of Palo Alto Investors's portfolio in Q2 2026, its #4 holding.
Palo Alto Investors first reported a position in Mirum Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Palo Alto Investors's 13F filing for Q2 2026, filed 17 Aug 2026.